|
NU T2DM PRS implementation |
Type 2 Diabetes - PRS Evaluation |
Northwestern University |
Case, Control |
|
|
|
|
|
Mayo clinic hearing loss implementation |
Hearing Loss |
Mayo Clinic |
Case, Control |
|
|
|
|
|
CHOP Part II- RESPONDERS |
Epilepsy/Antiepileptic drug response algorithm |
|
Case Only |
|
|
85% |
|
|
GH/UW |
Cardiorespiratory Fitness Algorithm (eMERGE Mayo Network Phenotype) |
GH/UW |
Case Only |
|
|
|
|
|
DR Marshfield Implementation |
Diabetic Retinopathy |
Marshfield Clinic Research Foundation |
Case, Control |
|
|
80%, 98% |
98%, 86% |
|
MGB |
Type 1 Diabetes |
|
Case, Control |
|
|
|
|
|
CCHMC Primary Validation |
Migraine |
|
Case Only |
|
|
92% |
|
|
PAD Mayo Implementation |
Peripheral Arterial Disease - 2012 |
Mayo Clinic |
Case Only |
|
|
91% |
86% |
|
CHOP Pneumonia |
Pneumonia- VUMC eMERGE v5.1 |
CHOP |
Case, Control |
|
|
|
|
|
Vanderbilt implementation |
Clostridium Difficile Colitis |
|
Case, Control |
|
|
100%, 100% |
|
|
Marshfield SLE Implementation |
SLE (Systemic Lupus Erythematosus) using SLICC (Systemic Lupus Internation Collaborating Clinics) Criteria |
Marshfield Clinic Research Institute |
Case Only |
|
|
|
|
|
Validation of ACEi-induced cough algorithm |
ACE Inhibitor (ACE-I) induced cough |
Mayo Clinic |
Case, Control |
|
|
100%, 96% |
|
|
Mayo Depression Algorithm Implementation |
Depression |
Mayo Clinic |
Case, Control |
|
|
|
|
|
CHOP implementation Case 3 |
Appendicitis |
|
Case Only |
10 |
|
50% |
|
|
Geisinger AAA Implementation |
Abdominal Aortic Aneurysm ( AAA ) |
Geisinger |
Case, Control |
|
|
94% |
100% |
|
Mayo_T2D_phaseIV_implementation |
Type 2 Diabetes - PRS Evaluation |
Mayo Clinic |
Case Only |
|
|
|
|
|
CCHMC - PART 1 |
Epilepsy/Antiepileptic drug response algorithm |
Cincinnati Children's Hospital Medical Center |
Case Only |
129 |
|
86% |
|
|
CRF_Columbia |
Cardiorespiratory Fitness Algorithm (eMERGE Mayo Network Phenotype) |
Columbia University |
Case Only |
2 |
|
|
|
|
DR Vanderbilt Implementation |
Diabetic Retinopathy |
Vanderbilt University |
Case, Control |
|
|
68%, 100% |
|
|
Warfarin-Columbia |
Warfarin dose/response |
Columbia University |
Case Only |
|
|
|
|
|
PAD Northwestern Implementation |
Peripheral Arterial Disease - 2012 |
Northwestern University |
Case, Control |
|
|
95%, 100% |
100%, 82% |
|
RA for NU eMERGEseq only population |
Rheumatoid Arthritis (RA) |
Northwestern University |
Case, Control |
|
|
|
|
|
ADHD Validation (CCHMC) |
ADHD phenotype algorithm |
Cincinnati Children's Hospital Medical Center |
Case, Control |
|
|
89%, 95% |
|
|
KPWHRI SLE Implementation |
SLE (Systemic Lupus Erythematosus) using SLICC (Systemic Lupus Internation Collaborating Clinics) Criteria |
KPWHRI |
Case, Control |
|
|
|
|
|
NU ACE Inhibitor (ACE-I) induced cough implementation |
ACE Inhibitor (ACE-I) induced cough |
Northwestern University The Feinberg School of Medicine |
Case, Control |
|
|
100%, 98% |
|
